Handelsbanken Fonder AB Takes $4.48 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Handelsbanken Fonder AB acquired a new position in Structure Therapeutics Inc. (NASDAQ:GPCR) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 165,000 shares of the company’s stock, valued at approximately $4,475,000. Handelsbanken Fonder AB owned approximately 0.29% of Structure Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in shares of Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares during the period. FNY Investment Advisers LLC acquired a new stake in Structure Therapeutics during the 4th quarter worth $40,000. Assetmark Inc. grew its stake in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after acquiring an additional 719 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Structure Therapeutics by 60.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after purchasing an additional 1,420 shares during the last quarter. Finally, Dearborn Partners LLC acquired a new stake in shares of Structure Therapeutics in the 3rd quarter worth $202,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 1.3 %

GPCR stock opened at $23.70 on Monday. Structure Therapeutics Inc. has a twelve month low of $22.33 and a twelve month high of $62.74. The company’s 50 day moving average is $27.37 and its two-hundred day moving average is $34.02. The stock has a market cap of $1.36 billion, a P/E ratio of -32.02 and a beta of -2.75.

Analysts Set New Price Targets

GPCR has been the topic of several analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.